Literature DB >> 30784952

Co-occurring substance use and mental disorders among adults with opioid use disorder.

Christopher M Jones1, Elinore F McCance-Katz2.   

Abstract

BACKGROUND: Co-occurring substance use and mental disorders among people with opioid use disorder (OUD) increase risk for morbidity and mortality. Addressing these co-occurring conditions is critical for improving treatment and health outcomes. There is limited recent research on the prevalence of co-occurring disorders, demographic characteristics associated with co-occurring disorders, and receipt of mental health and substance use treatment services among those with OUD. This limits the development of targeted and resourced policies and clinical interventions.
METHODS: Using 2015-2017 National Survey on Drug Use and Health data, prevalence of co-occurring substance use and mental disorders and receipt of mental health and substance use treatment services was estimated for adults aged 18-64 with OUD. Multivariable logistic regression assessed demographic and substance use characteristics associated with past-year mental illness (AMI) and serious mental illness (SMI) among adults with OUD as well as treatment receipt.
RESULTS: Among adults with OUD, prevalence of specific co-occurring substance use disorders ranged from 26.4% (95% CI:23.6%-29.4%) for alcohol to 10.6% (95% CI:8.6%-13.0%) for methamphetamine. Prevalence of AMI was 64.3% (95% CI:60.4%-67.9%) and SMI was 26.9% (95% CI:24.2%-29.8%). Receiving both mental health and substance use treatment services in the past year was reported by 24.5% (95% CI:21.5%-29.9%) of adults with OUD and AMI and 29.6% (95% CI:23.3%-36.7%) of adults with OUD and SMI.
CONCLUSIONS: Co-occurring substance use and mental disorders are common among adults with OUD. Expanding access to comprehensive service delivery models that address the substance use and mental health co-morbidities of this population is urgently needed. Published by Elsevier B.V.

Entities:  

Keywords:  Co-occurring disorders; Opioid overdose; Opioid use disorder; Receipt of mental health and substance use treatment; Serious mental illness

Mesh:

Year:  2019        PMID: 30784952     DOI: 10.1016/j.drugalcdep.2018.12.030

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  68 in total

1.  Mobilizing Primary Care to Address the Opioid Use Disorder Treatment Gap.

Authors:  Judith Steinberg; Alejandro Azofeifa; George Sigounas
Journal:  Public Health Rep       Date:  2019-08-07       Impact factor: 2.792

2.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

3.  Been There, Done That: Lessons from Vancouver's Efforts to Stem the Tide of Overdose Deaths.

Authors:  Michael R Krausz; James S H Wong; Ehsan Moazen-Zadeh; Kerry L Jang
Journal:  Can J Psychiatry       Date:  2020-03-16       Impact factor: 4.356

Review 4.  Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Authors:  Lauren E Hood; Jonna M Leyrer-Jackson; M Foster Olive
Journal:  Expert Opin Pharmacother       Date:  2020-02-27       Impact factor: 3.889

5.  Situating the Continuum of Overdose Risk in the Social Determinants of Health: A New Conceptual Framework.

Authors:  Ju Nyeong Park; Saba Rouhani; Leo Beletsky; Louise Vincent; Brendan Saloner; Susan G Sherman
Journal:  Milbank Q       Date:  2020-08-18       Impact factor: 4.911

6.  Forecasting Opioid Use Disorder at 25 Years of Age in 16-Year-Old Adolescents.

Authors:  Ralph E Tarter; Levent Kirisci; Gerald Cochran; Amy Seybert; Maureen Reynolds; Michael Vanyukov
Journal:  J Pediatr       Date:  2020-07-08       Impact factor: 4.406

7.  Multiple drug use disorder diagnoses among drug-involved hospitalizations in the United States: Results from the 2016 National Inpatient Sample.

Authors:  He Zhu; Li-Tzy Wu
Journal:  Drug Alcohol Depend       Date:  2020-06-12       Impact factor: 4.492

8.  Program development and implementation outcomes of a statewide addiction consultation service: Maryland Addiction Consultation Service (MACS).

Authors:  Sarah Sweeney; Kelly Coble; Elizabeth Connors; Kathleen Rebbert-Franklin; Christopher Welsh; Eric Weintraub
Journal:  Subst Abus       Date:  2020-08-19       Impact factor: 3.716

9.  Innovative payment to scale up access to medications for opioid use disorder.

Authors:  Daniel Polsky; Aditi P Sen; Samantha Arsenault
Journal:  Am J Manag Care       Date:  2020-07       Impact factor: 2.229

10.  Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.

Authors:  Yih-Ing Hser; Yuhui Zhu; Zhe Fei; Larissa J Mooney; Elizabeth A Evans; Annemarie Kelleghan; Abigail Matthews; Caroline Yoo; Andrew J Saxon
Journal:  Addiction       Date:  2021-06-22       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.